ProCE Banner Series

Navigating the Latest Evidence and Strategies for Renal Risk Reduction in T2D

Join 2 expert faculty in this live webinar as they provide a comprehensive review of the renal benefits associated with GLP-1 receptor agonists. Participants will explore the latest clinical data, proposed mechanisms, and evidence-based guidelines to optimize glycemic control and improve cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease.

  AAPA
  | AMA
  | ANCC
Who Should Attend

This program is intended for nephrologists, endocrinologists, primary care physicians, nurse practitioners, physician associates, and other healthcare professionals who manage patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

All Events

Navigating the Latest Evidence and Strategies for Renal Risk Reduction in T2D

Upcoming Events

November

06

2024

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Past Events

November

01

2024

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
David Charytan, MD, MSc

Norman S. Wilker Professor of Medicine
Director, Nephrology Division
New York University Grossman School of Medicine
New York, New York

ProCE Banner Faculty
Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Topics

T2D and CKD

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with CKD and T2D.

Target Audience
This program is intended for nephrologists, endocrinologists, primary care physicians, nurse practitioners, physician associates, and other healthcare professionals who manage patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the proposed mechanisms of renal benefits with GLP-1 RAs
  • Evaluate the latest efficacy and safety data for GLP-1 RAs in patients with T2D and CKD
  • Incorporate into practice the latest guidelines and evidence-based therapies to achieve glycemic goals and improve cardiorenal outcomes in patients with T2D and CKD

Accreditation

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Kidney Fund. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Kidney Fund

Supported by an educational grant from Novo Nordisk.